Analysis of prostate-specific antigen rebound interval in patients with prostate cancer receiving hormonal therapy and external-beam radiation therapy

Clinical Prostate Cancer

Volumn 3, Issue 1, 2004, Pages 43-48

  Jani, Ashesh B ^a   Al Qamari, Abbas ^a   Sapra, Bipin ^a   Krauz, Lani ^a   Awan, Azhar ^a   Kocherginsky, Masha ^a   Gillen, Daniel ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Androgen ablation; Biochemical failure; Digital rectal examination; Neoadjuvant therapy

Indexed keywords

BICALUTAMIDE; FLUTAMIDE; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CHRONOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PROSTATE CANCER; REVIEW; TREATMENT FAILURE;

EID: 3442883351     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2004.n.012     Document Type: Article

References (25)

1. Gronberg H. Prostate cancer epidemiology. Lancet 2003; 361:859-864.
2. Jani AB, Hellman S. Early prostate cancer: clinical decision-making. Lancet 2003; 361:1045-1053.
3. Pilepich MV, Krall JM, Al-Sarraf M, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostate carcinoma: a randomized comparative trial of the radiation therapy oncology group. Urology 1995; 45:616-623.
4. Laverdiere J, Gomez JL, Cusan L, et al. Beneficial effect of combination hormonal therapy admistered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37:247-252.
5. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003; 21:3972-3978.
6. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50:1243-1252.
7. Lawton CA, Winter K, Murray K, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 49:937-946.
8. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and externa irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360:103-106.
9. Jani AB, Basu A, Abdalla I, et al. The impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate- or high-risk prostate cancer. Am J Clin Oncol 2003; 26:382-385.
10. D'Amico AV, Schultz D, Loffredo M, et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA 2000; 284:1280-1283.
11. Jani AB, Kao J, Hellman S. Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: a complication-adjusted number-needed-to-treat analysis. Cancer 2003; 98:2351-2361.
12. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997; 37:1035-1041.
13. Pickles T, Duncan GG, Kim-sing C, et al. PSA relapse definitions-the Vancouver Rules show superior predictive power. Int J Radiat Oncol Biol Phys 1999; 43:699-700.
14. Kestin LL, Vicini FA, Martinez AA. Practical application of biochemical failure definitions: what to do and when to do it. Int J Radiat Oncol Biol Phys 2002; 53:304-315.
15. Pickles T, Kim-Sing C, Morris WJ, et al. Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int J Radiat Oncol Biol Phys 2003; 57:11-18.
16. Hanlon AL, Hanks GE. Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness. Int J Radiat Oncol Biol Phys 2000; 46:559-566.
17. Lu J. Statistical aspects of evaluating treatment and prognostic factors for clinically localized prostate cancer. Semin Urol Oncol 2000; 18:83-92.
18. Jani AB, Chen MH, Vaida F, et al. PSA-based outcome analysis after radiation therapy for prostate cancer: a new definition of biochemical failure after intervention. Urology 1999; 54:700-705.
19. Efton B, Tibshirani RJ. An Introduction to the Bootstrap. New York: Chapman & Hall/CRC Press, 1998:10-85.
20. Fleming TR, Lin DY. Survival analysis in clinical trials: past developments and future directions. Biometrics 2000; 56:971-983.
21. Johnstone PA. Biochemical failure after definitive therapy of prostate cancer: defining the chicken switch. Int J Radiat Oncol Biol Phys 2003; 55:859-860.
22. Hanlon AL, Pinover WH, Horwitz EM, et al. Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Oncol Biol Phys 2001; 50:845-849.
23. Cavanagh W, Blasko JC, Grimm PD, et al. Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer. Semin Urol Oncol 2000; 18:160-165.
24. Vicini FA, Kestin LL, Martinez AA. The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma. Cancer 2000; 88:2305-2318.
25. Coen JJ, Chung CS, Shipley WU, et al. Influence of follow-up bias on PSA failure after external beam radiotherapy for localized prostate cancer: results from a 10-year cohort analysis. Int J Radiat Oncol Biol Phys 2003; 57:621-628.